✉news ScienceBiology first seen 9 h ago, last 59 min ago, peak #20
Study identifies DHODH as key target of glioblastoma drug QC6352
Original: DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells
Researchers report that DHODH, an enzyme involved in pyrimidine synthesis, is the key target through which the KDM4 inhibitor QC6352 acts against glioblastoma stem cells. The finding, published in Nature, suggests the compound's anti-cancer effect works via metabolic disruption rather than its intended epigenetic pathway, with implications for treating this aggressive brain cancer.
Why now: The new Nature paper offers a potential new therapeutic target for glioblastoma, an aggressive cancer with few effective treatments.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/1251486